/MEDIA / Dialogue with stakeholders

DIALOGUE WITH STAKEHOLDERS - Dialogue with stakeholders

  • Industry Perspective - Daniel Schneider

    Evidence-based test in vanguard of march towards personalised medicine

    Switzerland-based Daniel Schneider is the Director of International Marketing at Genomic Health, responsible for marketing Oncotype DX tests across Europe.

    The Oncotype DX assay personalises early-stage breast cancer treatment by identifying which patients are likely to benefit from chemotherapy and which can avoid the toxicities and costs associated with that treatment.

  • Medical Perspective - Didier Jacqmin

    More patients needed for clinical trials, says top urologist

    Didier Jacqmin, of the European Association of Urology (EAU), is a professor of urology based in the European Parliament-city of Strasbourg, France.

    The EAU’s stated mission is to raise the level of urological care throughout Europe and beyond. It’s the leading authority within Europe on urological practice, research and education and represents more than 16,000 medical professionals who together strive to create forward-looking solutions for continuous improvement, professional growth and knowledge sharing.

  • Industry Perspective - Dr Andreas Penk

    EU healthcare systems ‘must keep pace with science’ says Pfizer chief 

    Dr Andreas Penk is Head of Pfizer Oncology Europe/Africa, and Middle East as well as Chairman of the Board of Pfizer Germany.

    When asked what kind of EU policies are needed to strengthen personalised cancer medicine and to increase patient access to personalised cancer therapies, Dr Penk is clear that adjustments need to be made to take into account the leaps in scientific progress.

  • Patient Prospective - Dr Stanimir Hasardzhiev

    Dr Stanimir Hasardzhiev is one of the founders (and current chairperson) of the National Patients’ Organisation of Bulgaria (NPO) – the biggest patients’ umbrella organisation in the country with 85 disease-specific member groups. 

    Alongside his other patient advocacy work, in 2013 Stanimir became a board member of the European Patients’ Forum (EPF) which, among other activities, represents specific chronic disease groups at EU level. 

  • Industry Perspective - Emmanuel Chantelot

    Biotech industry: living longer and healthier lives

    Emmanuel Chantelot is Head of International Government Relations at Shire Pharmaceuticals and has been Chairman of the EuropaBio Healthcare Council since 2012.

    EuropaBio is the European Association of BioIndustries. Its members are involved in research, development, testing, manufacturing and commercialisation of biotech products and processes in human and animal healthcare, diagnostics, bioinformatics, chemicals, crop protection, agriculture, food and environmental products and services. EuropaBio also counts a number of National Biotech Associations in its membership who in turn represent more than 1,800 biotech SMEs.

  • Industry Perspective - Eric Dishman

    Healthcare future ‘built on computing and data’ says Intel’s Dishman 

    US-based Eric Dishman is an Intel Fellow...

  • Industry Perspective - Gary Lee Geipel

    Eli Lilly: Keeping PACE with patient needs

    Gary Geipel is passionate about healthcare. He has to be. 

    Gary is a Senior Director with pharmaceutical company Eli Lilly and Company, and his particular sphere of responsibility is the PACE initiative (Patient Access to Cancer care Excellence).

  • Patient Prospective - Jayne Bressington

    Getting to the gist of rare-cancer issues 

    Jayne Bressington is Patient Director for the PAWS-GIST national alliance and a trustee of GIST Support UK.

    The PAWS section of the name is an acronym for paediatric adolescent wild-type syndromic, while GIST stands for gastrointestinal stromal tumour.

[ 1 | 2 | next ]

» Back to categories